Get the Stockscreener App
8.40
2.67%
-0.23
After Hours:
8.63
0.23
+2.74%
Exagen Inc stock is traded at $8.40, with a volume of 517.34K.
It is down -2.67% in the last 24 hours and up +20.34% over the past month.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
See More
Previous Close:
$8.63
Open:
$8.78
24h Volume:
517.34K
Relative Volume:
1.61
Market Cap:
$183.63M
Revenue:
$52.55M
Net Income/Loss:
$-23.69M
P/E Ratio:
-8.9362
EPS:
-0.94
Net Cash Flow:
$-15.29M
1W Performance:
+16.34%
1M Performance:
+20.34%
6M Performance:
+110.00%
1Y Performance:
+330.77%
1-Day Range:
$8.37
$8.87
1-Week Range:
$7.12
$9.10
52-Week Range:
$1.78
$9.10
Exagen Inc Stock (XGN) Company Profile
Name
Exagen Inc
Sector
Industry
Phone
(760) 560-1501
Address
1261 LIBERTY WAY, VISTA, CA
Compare XGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
8.40 | 188.66M | 52.55M | -23.69M | -15.29M | -0.94 |
|
TMO
Thermo Fisher Scientific Inc
|
467.68 | 180.17B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
197.16 | 146.07B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
534.31 | 46.01B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
114.81 | 33.53B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
185.86 | 32.56B | 15.50B | 1.33B | 2.16B | 7.34 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-23-25 | Initiated | Craig Hallum | Buy |
| Aug-05-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Apr-15-21 | Initiated | Canaccord Genuity | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cowen | Outperform |
| Oct-14-19 | Initiated | William Blair | Outperform |
View All
Exagen Inc Stock (XGN) Latest News
What markets is Exagen Inc. expanding into Is LILA stock a good long term investment optionExpert Picks Data Feed For Consistent Profits - jammulinksnews.com
What risks could impact Exagen Inc. stock performanceDaily Upside Movement Prediction With Data - Newser
Published on: 2025-07-31 02:36:55 - Newser
What makes Exagen Inc. stock price move sharplyPattern Recognition Tool for ROI Investors - Newser
What is the risk reward ratio of investing in Exagen Inc. stockRetirement Planning Forecasts For Consistent Profits - jammulinksnews.com
Exagen price target raised to $11 from $8 at Canaccord - TipRanks
Exagen Inc. Reports Record Revenue Amidst Growth Challenges - TipRanks
Exagen price target raised to $10 from $7 at Cantor Fitzgerald - TipRanks
Exagen outlines $65M–$70M 2025 revenue target and positive adjusted EBITDA trajectory while advancing biomarker pipeline - MSN
Exagen stock price target raised to $10 from $7 at Cantor Fitzgerald - Investing.com Nigeria
KeyBanc upgrades Exagen on improved revenue visibility - TipRanks
Visual analytics tools that track Exagen Inc. performanceLow Risk Stock Selection Strategy Guide - Newser
KeyBanc upgrades Exagen stock to Overweight on improved pricing and growth - Investing.com Nigeria
Chart based analysis of Exagen Inc. trendsTop Stock Picks with Forecast Accuracy - Newser
Key metrics from Exagen Inc.’s quarterly dataHigh Probability Trade Outcome Prediction - Newser
Why Exagen Inc. stock attracts strong analyst attentionLow Risk Stock Selection Strategy Guide - Newser
Exagen Inc. Reports Record Q2 2025 Revenue - TipRanks
Exagen 2025 Q2 Earnings Misses Targets as Net Loss Widens 49.7% - AInvest
Exagen Q2 Revenue Jumps 14 Percent - AOL.com
Exagen's Q2 2025: Unpacking Contradictions in Volume Growth, ASP Expectations, and Biopharma Revenue - AInvest
Exagen Inc. To Announce Second Quarter 2025 Financial Results On July 29, 2025 - Barchart.com
Earnings call transcript: Exagen Q2 2025 revenue surpasses expectations - Investing.com
EXAGEN INC. SEC 10-Q Report - TradingView
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Exagen’s Revenue Rises, But Profit Remains Elusive In Q2 - Finimize
Exagen Inc. Reports Strong Q2 2025 Results - The Manila Times
Applying big data sentiment scoring on Exagen Inc.Real-Time Signal Tracking with Entry Level - Newser
Published on: 2025-07-29 06:38:44 - Newser
How Exagen Inc. stock performs during market volatilitySafe Entry Strategy with High Win Rate - Newser
Exagen Inc (XGN) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Growth Initiatives By GuruFocus - Investing.com Canada
Sector Rotation Brings Exagen Inc. Into FocusSafe Entry Stock Watch Suggestions for Cautious Traders - metal.it
Is Exagen Inc. a growth stock or a value stockStock Strategy Signals For Consistent Profits - jammulinksnews.com
Exagen Inc (XGN) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Exagen Inc (XGN) Q2 2025: Everything You Need To Know Ahead Of E - GuruFocus
Is Exagen Inc. stock overvalued or undervaluedBreakout portfolio performance - jammulinksnews.com
What catalysts could drive Exagen Inc. stock higher in 2025Build wealth steadily with proven investment techniques - jammulinksnews.com
What are analysts’ price targets for Exagen Inc. in the next 12 monthsAchieve explosive financial results today - jammulinksnews.com
What are Exagen Inc. company’s key revenue driversAmplify your gains with low-risk picks - jammulinksnews.com
Is Exagen Inc. Stock a Smart Buy in 2025 Investment Analysis InsideFree Market Dynamics Reports - Newser
New Product Launches: Will They Boost Exagen Inc. Stock in 2025Low Risk Stock Strategies - Newser
Exagen Inc Stock (XGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):